Micronutrient supplementation in metabolic syndrome
- Conditions
- Metabolic SyndromeMetabolic and Endocrine - Metabolic disorders
- Registration Number
- ACTRN12621000678897
- Lead Sponsor
- niversity of Otago, Dunedin
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 72
1 - Male or female aged greater than or equal to 18 years
2 - Central/abdominal obesity (i.e. waist circumference greater than or equal to 94 cm for males, greater than or equal to 80 cm for females or BMI greater than or equal to 30 kg/m2)
3 - And any two of the below:
a) Hyperglycemia (i.e. fasting glucose greater than or equal to 5.6 mmol/L or taking medication for this condition)
b) Raised triglycerides (i.e. TG greater than or equal to 1.7 mmol/L or taking medication for this condition)
c) Lowered HDL (HDL less than 1.0 mmol/L males, less than 1.3 mmol/L females or taking medication for this condition)
d) Hypertension (i.e. blood pressure greater than 130 systolic or greater than 86 diastolic or taking medication for this condition)
4 - CRP greater than 3mg/L (i.e. high risk of cardiovascular disease - CVD)
1 - Acute illness within previous 2 weeks
2 - Taking anti-inflammatory medication (e.g. corticosteroids)
3 - Suffering from inflammatory conditions (e.g. active malignancy, rheumatoid arthritis, lupus, inflammatory bowel disease)
4 - Pregnant or breastfeeding
5 - Taking micronutrient (vitamin/mineral) supplements
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Effect of intervention on plasma high-sensitivity C-reactive protein (hs-CRP) concentrations (Immunoturbidimetric, latex immunoassay)[ Baseline (prior to intervention), 6 weeks and 12 weeks (primary endpoint) post the commencement of intervention. ]
- Secondary Outcome Measures
Name Time Method